Objetivo
There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed to elicit neutralising Abs. Several families of immunogens which mimic gp41 in its fusion intermediate conformations are already available and others will be designed using modelisation approaches. Candidates will be submitted to a thorough biophysical characterisation followed by a preclinical development in order to identify the most promising for clinical evaluation. A crucial selection parameter is the capacity of antigens to elicit neutralising Abs using internationally standardized assays. Since sexual transmission accounts for more than 90% of HIV infection, the capacity of Abs to inhibit infection at the mucosal level will also be determined. This cross-disciplinary project gathers top European scientists with expertise in protein engineering and characterisation, adjuvantation, formulation for systemic and mucosal delivery, evaluation of functional antibody response, efficacy testing in animal models, medium to large scale vaccine production as well as conduct of clinical trials in both developed and third-world countries. In contrast to previous more empirical attempts, this project is based on the rational exploitation of the knowledge on the mechanism of HIV entry and is thus a promising approach to generate a protective vaccine. It will be the first European project targeting intermediate conformations of gp41 and it could complement/synergize other international strategies focusing on the membrane proximal region of gp41 or gp140 trimer to induce neutralising Abs or aiming at reducing the viral load by eliciting a cellular immunity against HIV.
Ámbito científico
Palabras clave
Convocatoria de propuestas
FP7-HEALTH-2007-A
Consulte otros proyectos de esta convocatoria
Régimen de financiación
CP-IP - Large-scale integrating projectCoordinador
69007 Lyon
Francia
Ver en el mapa
Participantes (18)
13353 Berlin
Ver en el mapa
18071 Granada
Ver en el mapa
93053 REGENSBURG
Ver en el mapa
2970 Hoersholm
Ver en el mapa
38027 GRENOBLE
Ver en el mapa
BT7 1NN Belfast
Ver en el mapa
3400 Klosterneuburg
Ver en el mapa
1024 Budapest
Ver en el mapa
75015 PARIS 15
Ver en el mapa
SW17 0RE London
Ver en el mapa
NW3 2QG London
Ver en el mapa
6110 Port-Au-Prince
Ver en el mapa
La participación finalizó
1227 CAROUGE
Ver en el mapa
67081 Strasbourg
Ver en el mapa
75654 Paris
Ver en el mapa
01707 NEYRON
Ver en el mapa
SW7 2AZ LONDON
Ver en el mapa
GU2 7XH Guildford
Ver en el mapa